Loading
Receptors, G-protein-coupled / Alzheimer Disease / Neurodegenerative Diseases · Journal article
Annals of Medicine · January 23, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review integrating preclinical and mechanistic evidence for GPR3 as a potential therapeutic hub across neural, metabolic, immune, and reproductive systems. The authors acknowledge dual and sometimes conflicting roles (e.g., promoting amyloid-β in Alzheimer's disease while providing neuroprotection in Parkinson's models), translation barriers, and heterogeneous underlying studies, limiting definitive clinical translation.
Narrative review article. Literature review spanning preclinical studies and mechanistic investigations across multiple organ systems and disease models; no clinical population enrolled.. Multi-database international literature review (PubMed, Web of Science); review conducted at Department of Neurology, Affiliated Hospital of Zunyi Medical University, China..
GPR3 modulates neuronal survival, synaptic plasticity, and microglial activity via cAMP/PKA, PI3K/Akt, and β-arrestin signaling pathways GPR3 promotes amyloid-β formation in Alzheimer's disease models but provides neuroprotection in Parkinson's disease models GPR3 maintains oocyte meiotic arrest in the ovary and activates thermogenic genes in adipose tissue
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies GPR3 as a potential multi-system drug target but does not provide evidence sufficient to guide clinical practice. Clinicians should note the acknowledged dual roles and translation challenges that require further research before any therapeutic application.
This is a narrative review synthesizing heterogeneous preclinical and mechanistic evidence across multiple organ systems without meta-analysis, original clinical trials, or definitive human efficacy data to support GPR3 as a therapeutic target.
As stated by the source record.
Quoted from the source exactly as published.
This review identifies GPR3 as a potential multi-system drug target but does not provide evidence sufficient to guide clinical practice. Clinicians should note the acknowledged dual roles and translation challenges that require further research before any therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. GPR3(G-protein-coupled receptor 3), an orphan G-protein-coupled receptor (GPCR) with constitutive Gs activity, is expressed in the brain, liver, ovary, and other tissues, regulating cell proliferation, differentiation, and apoptosis across the nervous, reproductive, immune, and metabolic systems. This review synthesizes evidence on its integrated signaling and physiological functions to address the lack of a comprehensive multisystem pathophysiology overview.Methods. A systematic literature search was conducted on PubMed and Web of Science, using keywords such as "GPR3", "GPCR", "neurodegeneration", "metabolism", "immune", "reproduction", "agonist", "inhibitor", and "therapeutic target". This search identified GPR3's roles in neurodegenerative diseases, immune inflammation, reproduction, and energy metabolism. The analysis focused on signaling pathways, ligand regulation, and therapeutic potential.Results. The research indicates that GPR3 is involved in neuronal survival, synaptic plasticity, and microglial activity via the cAMP/PKA, PI3K/Akt, and β - arrestin pathways. It promotes amyloid - β formation in Alzheimer's disease (AD), yet provides neuroprotection in Parkinson's disease (PD) models. It may contribute to anxiety/depression - like states, maintain oocyte meiotic arrest in the ovary, and activate thermogenic genes in adipose tissue. GPR3 modulates immune responses. Using oleic acid (OA) and diphenyleneiodonium (DPI) as activators, and AF64394 and cannabidiol (CBD) as antagonists, it shows potential in disease models.Conclusion. GPR3 acts as a central molecular hub integrating neural, metabolic, immune, and reproductive signaling, highlighting its potential as a therapeutic target for chronic multisystem disorders. However, its dual roles in certain pathologies and translation challenges necessitate further research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.